BL0020 / Shanghai Best-Link Biosci - LARVOL DELTA

BL0020, a novel targeting tumor microenvironment (TME) nano-mediated polypeptide-drug conjugate (NMPDC), in patients with advanced solid tumors: Results from a phase I study (ESMO 2025) - "Conclusions BL0020 demonstrated a manageable safety profile and encouraging efficacy in advanced solid tumors, particularly in relapsed SCLC and malignant thymoma. Legal entity responsible for the study Shanghai Best-Link Bioscience, LLC."

Biomarker • Clinical • Metastases • P1 data • Tumor microenvironment • Hepatocellular Cancer • Liver Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • Thymoma • Thymus Cancer

Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Recruiting | Sponsor: Shanghai Best-Link Bioscience, LLC | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer

Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Shanghai Best-Link Bioscience, LLC | Initiation date: Jul 2023 ➔ Oct 2023

Metastases • Trial initiation date • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer

Phase I Study of BL0020, a Novel Anti-tumor Drug, in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Shanghai Best-Link Bioscience, LLC

Metastases • New P1 trial • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Triple Negative Breast Cancer